The goal of this clinical trial is to study a personalized regime of lutetium-177 (177Lu) prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT) in patients with progressive and/or symptomatic, inoperable PSMA-expressing cancers of prostatic or other origins.
The main questions it aims to answer are:
* To establish a dosimetry-based, personalized regime of 177Lu-PSMA
* To report on the efficacy of personalized 177Lu-PSMA
Participants (stratified by risk factors of toxicity) will receive up to 6 cycles of a personalized activity of 177Lu-PSMA based on renal dosimetry. In the phase 1, the prescribed absorbed dose to the kidney will be escalated, to determine the regime that will be administered in the phase 2. The best response within 12 months after the first cycle will be assessed. Salvage treatment of 3 cycles may be offered to responders after re-progression.

Start Date01 Mar 2025

Sponsor / Collaborator

Centre Hospitalier Universitaire (CHU) de Québec-Université Laval

[+1]

NCT05941806

/ Not yet recruitingPhase 3IIT

Prophylactic Use of Tamsulosin in the Prevention of Post-operative Urinary Retention in Men After Rectum Resection: a Double-blind Placebo-controlled Clinical Trial

The study will be a phase III double-blind randomized clinical trial. Participants will be recruited from the Department of General Surgery of the CHU de Québec - Saint-François-d'Assise and Hôtel-Dieu de Québec. The primary outcomes are the incidence of postoperative urinary retention in men undergoing rectal resection and the efficacy of prophylactic tamsulosin to prevent this type of complication.The secondary outcomes are the length of stay between experimental and placebo groups, the number of urinary catheterizations, the number of urine catheter reinsertions and total duration of urinary catheter being in-situ.

Start Date01 Aug 2023

Sponsor / Collaborator

Centre Hospitalier Universitaire (CHU) de Québec-Université Laval

NCT05327647

/ RecruitingPhase 2IIT

A Phase II Randomized Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer

This is a phase II randomized controlled clinical trial comparing standard induction BCG versus bicalutamide and standard induction BCG among patients with non-muscle invasive bladder cancer.

Start Date23 Jun 2022

Sponsor / Collaborator

Centre Hospitalier Universitaire (CHU) de Québec-Université Laval

[+2]

100 Clinical Results associated with Centre Hospitalier Universitaire (CHU) de Québec-Université Laval

0 Patents (Medical) associated with Centre Hospitalier Universitaire (CHU) de Québec-Université Laval

225

Literatures (Medical) associated with Centre Hospitalier Universitaire (CHU) de Québec-Université Laval

01 Feb 2025·Operative Neurosurgery

Development and Validation of a Novel Human-Fixed Cadaveric Model Reproducing Cerebrospinal Fluid Circulation for Simulation of Endoscopic Endonasal Skull Base Surgery

Article

Author: Beaulieu, Olivier ; Gosselin, Laura-Elisabeth ; Nadeau, Sylvie ; Champagne, Pierre-Olivier ; Chamberland, Mathieu ; Morin, Nicolas ; Gariépy, Charles

BACKGROUND AND OBJECTIVES:Endoscopic endonasal surgery is a well-established surgical approach to the skull base. Surgeons need a reusable long-lasting tool to acquire the skills needed for skull base reconstruction. The aim of this study was to elaborate and validate a human formalin-fixed cadaveric model that reproduces a realistic cerebrospinal fluid (CSF) circulation and that adequately renders a CSF leak.METHODS:An external ventricular drain that connects with a peristaltic pump is placed in the subarachnoid space, which allows a water circulation that reproduces CSF circulation. Intracranial pressure is measured in real time. Endoscopic endonasal skull base approaches are performed, to create different skull base openings and CSF leaks. Participants were tasked with reconstruction of the defects using a standardized multilayered approach, with the goal of obtaining a watertight closure under normal intracranial pressure ranges. Compiled data included time of reconstruction, years of experience of participants, and success/failure to achieve a watertight reconstruction. A Likert questionnaire was also used.RESULTS:The cadaveric model reproduced CSF circulation in 4 types of dural defects: sellar, suprasellar, transcribriform, and transclival. Intracranial pressures were similar to physiological conditions and were reproducible. Each model was tested multiple times, over several months. Success rates concurred with training levels (r = .8282 and P = .0017). A strong inverse correlation was also found between years of experience and time of reconstruction (r = .4977 and P < .0001). Participants agreed that the model was realistic (median Likert score of 4), and they strongly agreed that it allowed for the improvement of their surgical skills (median Likert score of 5).CONCLUSION:This novel human-fixed cadaveric model for CSF circulation is efficient and adequately reproduces surgical conditions for skull base approaches. The model is unique, easy to reproduce, and reusable. It can be used as a tool for teaching and for research purposes.

19 Jan 2025·Physics in Medicine & Biology

Low dose contrast enhancement of biodegradable low-density stents by an approach balancing radiopaque coatings and beam filtration

Article

Author: Bazalova-Carter, Magdalena ; Lescot, Theophraste ; Zekraoui, Souheib ; Mantovani, Diego ; Fortin, Marc-André ; Ravanbakhsh, Samira

AbstractObjective. Biodegradable cardiovascular stents made of thin, low atomic number metals (e.g. Zn, Mg, Fe) are now approved for clinical use. However, poor contrast under x-ray imaging leads to longer surgical times, high patient exposure, and sometimes stent misplacement. This study aimed at enhancing the visibility of low-Z metal stents under x-ray imaging, by combining high-Z metal coatings and beam filtration. Approach. Photon energy spectra from W-anode x-ray beams operated at 80 and 120 kVp, were generated by the SpekCalc and BEAMnrc softwares. The contrast produced by Fe stent struts (50–10 μm W coatings), as well as dose and air kerma values (by BEAMnrc), were simulated. Several types of beam hardening filters (Sn: 0.1, 0.2 mm; Cu: 0.2, 0.7 mm) were also applied. Then, Fe foils (50 µm) with W coatings (2–3 µm-thick) were fabricated by magnetosputtering. These samples were x-ray visualized, for quantification of contrast between W-coated and uncoated Fe samples. Fe struts (50 µm) were also coated with W (3.8 ± 0.2 µm), and stent-like objects were x-ray visualized. Main results. Fe samples attenuate 6.4% (120 kVp) and 10.1% (80 kVp) spectra photons, and 25% and 34.5% for W-coated Fe samples (SpekCalc). BEAMnrc calculations revealed the highest contrast improvement in a 120 kVp beam (36.4%, and 38.5%) for W-coated and uncoated Fe samples with Sn (0.2 mm), and Cu + Sn (0.2 + 0.2 mm) filters. Experimentally, the highest contrasts between Fe and W–Fe foils, were obtained with 0.2 mm Sn (77 ± 7% contrast increase at 80 kV). The dose was also strongly reduced (70% and 75%, for 80 and 120 kVp beams). Finally, for 3D Fe stents visualized at 80 kVp, the highest CNR and CNRD values were achieved with 0.1 mm Sn (18.5 × and 20.1 mGy−1; compared to 15.0 × and 12.0 mGy−1 in no-filter condition). Significance. The contrast of Fe-based stents in x-ray imaging is improved by addition of a thin layer of W and beam filtration with Sn. The precision and rapidity of biodegradable stents implantation would be improved thereby, as well as the dose to patients.

01 Dec 2024·Annals of Surgical Oncology

ASO Visual Abstract: Predictive Value of C-Reactive Protein for Infectious Complications after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy—A Single-Center Prospective Study

Article

Author: Soucisse, Mikaël ; De Guerké, Lara ; Singbo, Narcisse ; Piedimonte, Sabrina ; Charbonneau, Janyssa ; Leblanc, Guy ; Tremblay, Jean-François ; Auclair, Marie-Hélène ; Brind'Amour, Alexandre ; Gervais, Mai-Kim ; Sideris, Lucas ; Fortin, Suzanne

100 Deals associated with Centre Hospitalier Universitaire (CHU) de Québec-Université Laval

100 Translational Medicine associated with Centre Hospitalier Universitaire (CHU) de Québec-Université Laval

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 02 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

AGU-25 ( IL1R1 )	Retinal Diseases More	Preclinical
RM-581	Pancreatic Cancer More	Discovery

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis